Abstract:Peroxisome proliferator‐activated receptor gamma (PPARγ) is a ligand‐activated transcription factor with anti‐inflammatory properties. One of the anti‐inflammatory mechanisms is antagonism of nuclear factor kappa B (NFκB) activity. Synthetic activators of PPARγ are known to inhibit the formation of atherosclerotic lesions in animal models. In contrast, transgenic mice expressing a dominant negative (DN) mutant of PPARγ specifically in vascular smooth muscle cells (SMC) exhibited exacerbated atherosclerosis with increased expression of NFκB target genes in aortic tissue. Based on this, we hypothesized that the exaggerated atherosclerosis in these mice is due to increased NFκB‐mediated inflammation. We tested the role of SMC PPARγ in controlling inflammatory gene expression. Mesenteric SMCs were cultured from transgenic mice designed to conditionally express wild‐type (WT) or DN PPARγ (P467L) in response to Cre‐recombinase (delivered by adenovirus). PPARγ expression remained silent in control SMC infected with AdGFP but was induced in SMC infected with AdCRE. The PPARγ target gene aP2 was induced in WT‐Cre SMC but not in P467L‐Cre SMC. TNF‐α, IL‐1β or LPS all induced NFκB target gene (VCAM1, MCP‐1, iNOS and MMP9) expression in WT SMC infected with AdGFP (WT‐GFP). Expression of these genes was reduced in WT SMC infected with AdCRE (WT‐Cre). For example, TNF‐α induced MMP9 expression by 6.0±0.3‐fold in WT‐GFP vs 0.7±1.2‐fold in WT‐Cre (p<0.01). In contrast, the ability of TNF‐α to induce NFκB target gene expression was increased in P467L cells infected with AdCRE (P467L‐Cre) compared to those infected with AdGFP (P467L‐GFP, MMP9: 6.3±0.2 vs 3.2±0.5, p<0.01). Similarly, TNF‐α or LPS‐induced NFκB activity assessed by an adenovirus‐NFκB‐Luciferase reporter was blunted in WT‐Cre SMC but increased in P467L‐Cre SMC. Although expression of the NFκB subunit, p65, was not altered in any of these cells, nuclear export of p65 was accelerated in WT‐Cre SMC, but prevented in P467L‐Cre SMC. WT PPARγ co‐precipitated with p65, but the interaction between p65 and P467L PPARγ was severely impaired in HEK293 cells. Finally, to examine mechanisms in vivo , we crossbred transgenic mice expressing WT PPARγ specifically in SMC (S‐WT) with mice expressing luciferase under control of a NFκB‐responsive promoter. TNF‐α (500 ng/ml, 24 hr)‐induced NFκB activity was decreased in aorta and carotid artery from S‐WT mice compared to control mice (aorta: 4.7±1.1 vs 6.7±0.7, p<0.05, carotid artery: 4.0±0.6 vs 8.7±1.2, p<0.01). We conclude that PPARγ in SMC exerts anti‐inflammatory effects by inhibition of NFκB activity through a mechanism promoting nuclear export of p65. This mechanism is abolished by P467L mutation in PPARγ. Support or Funding Information This work was supported by National Institutes of Health Grants HL048058, HL062984 and HL08307 (to Curt D. Sigmund).

Abstract 124: RhoBTB1, a Novel PPARγ Target Gene, Rescues Hypertension and Vascular Dysfunction Caused by PPARγ Dysfunction

RhoBTB1 is a Novel Gene Protecting Against Hypertension

The Role of Vascular Smooth Muscle RhoBTB1 in Hypertension

RhoBTB1 Protects Against Hypertension and Arterial Stiffness by Restraining Phosphodiesterase 5 Activity

Abstract 110: Vascular Smooth Muscle RhoBTB1 Protects from Hypertension and Arterial Stiffness by Cullin-3 Dependent Ubiquitination of Phosphodiesterase 5

Hypertension-Causing Mutation in Peroxisome Proliferator–Activated Receptor Γ Impairs Nuclear Export of Nuclear Factor-κB P65 in Vascular Smooth Muscle

Distinct Functions of Vascular Endothelial and Smooth Muscle PPARγ in Regulation of Blood Pressure and Vascular Tone

PPARδ Agonist Prevents Endothelial Dysfunction Via Induction of Dihydrofolate Reductase Gene and Activation of Tetrahydrobiopterin Salvage Pathway

Abstract 269: RBM20 Knockout Ameliorates Angiotensin II Induced Hypertension and Cardiac Hypertrophy

Abstract 55: PPAR-δ Binding to Heme Oxygenase 1 Promoter Prevents Angiotensin II Induced Vascular and Adipocyte Dysfunction in a Model of Renovascular Hypertension

Mutation in the PPARγ Ligand Binding Domain Impairs the Anti‐inflammatory Action of PPARγ

DP1 (Prostaglandin D2 Receptor 1) Activation Protects Against Vascular Remodeling and Vascular Smooth Muscle Cell Transition to Myofibroblasts in Angiotensin II–Induced Hypertension in Mice

Activation of PPAR-γ Ameliorates Pulmonary Arterial Hypertension Via Inducing Heme Oxygenase-1 and P21(waf1): an in Vivo Study in Rats.

Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality.

Hypotension, lipodystrophy, and insulin resistance in generalized PPARγ-deficient mice rescued from embryonic lethality

Abstract 049: Abrogation Of Transglutaminase 2 In Vascular Smooth Muscle Cells Attenuates Doca/salt Induced Hypertension In Male Mice

PPARδ activation protects endothelial function in diabetic mice

In vivo PPAR|[alpha]| activation attenuates cerebrovascular endothelial dysfunction via impeding NADPH oxidase-derived superoxide and augmenting tetrahydrobiopterin in mineralocorticoid hypertension

Endothelium-Specific Gtp Cyclohydrolase I Overexpression Attenuates Blood Pressure Progression In Salt-Sensitive Low-Renin Hypertension

PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension

Abstract 399: Whole-Body Deletion of PPAR? in Mice Increases Sympathetic Nerve Activity